AAT-076 is under clinical development by AskAt and currently in Phase II for Pain. According to GlobalData, Phase II drugs for Pain have a 46% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how AAT-076’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

AAT-076 overview

RMX-1001 is under development for the treatment of pain including cancer pain and post surgical dental pain and unspecified cancer indications. It is administered through oral and intravenous route. The drug candidate acts by targeting cyclooxygenase 2 (COX-2).

AskAt overview

AskAt is a new kind of life sciences company that is committed to revolutionizing the drug discovery process and delivering truly ground breaking medications to waiting patients around the world. The company is headquartered in Nagoya, Japan.

For a complete picture of AAT-076’s drug-specific PTSR and LoA scores, buy the report here.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.